Leidos nabs $12.4M contract to support vaccine efficacy
Leidos has won a single-award $12.4 million contract to improve the efficacy of vaccine candidates for prevention of anthrax and West Nile virus.
Leidos has won a single-award $12.4 million contract to improve the efficacy of vaccine candidates for prevention of anthrax and West Nile virus.
Under the contract, awarded by the National Institute of Allergy and Infectious Diseases, Leidos will prepare and assess formulations of their lead immune boosting agent compound, the company said in a release.
In order to complete the work under the contract, Leidos assembled a team that includes the Infectious Disease Research Institute, the Hawaii Biotech Institute, Pfenex Inc., Duke University, Molecular Diagnostics Services, the IIT Research Institute Inc., and Colorado State University.